Symbols

BIOL(Delisted)

Biolase·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 0

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About BIOL

Biolase, Inc.

A world's leading dental laser company

Industry

Established Date

Listing Date

11/12/1992

Exchange

NASDAQ Stock Exchange

Full-time Employees

157

Fiscal Year Ends

12-31

Website

www.biolase.com

Security Type

Common stock

Office address

27042 Towne Centre Drive, Suite 270, Lake Forest, California 92610

Business

Introduction

Biolase, Inc., was founded in Delaware in 1987. It is a company dedicated to the research, production and sale of dental and pharmaceutical laser products, as well as the distribution of dental imaging equipment and other technologies aimed at improving dental and medical applications. The company's laser system enables dentists, periodontists, endodontists, oral surgeons and other specialists to perform cosmetic and complex surgery in a minimally invasive manner. The company's system is intended to provide a clinical template for previously traditional surgeries performed with drills, scalpels and other dental equipment that are less painful and have a faster recovery. Biolase, Inc., which has been cleared from the US Food and Drug Administration to open the market for its laser systems in the United States, can also sell its laser systems in Canada, the European Union and other international markets.

Company Financials

EPS

BIOL has released its 2023 Q4 earnings. EPS was reported at -1.76, versus the expected -2.56, beating expectations. The chart below visualizes how BIOL has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

BIOL has released its 2024 Q1 earnings report, with revenue of 10.13M, reflecting a YoY change of -3.21%, and net profit of -6.49M, showing a YoY change of -10.87%. The Sankey diagram below clearly presents BIOL's revenue sources and cost distribution.